CA2239203A1 - Drug therapy - Google Patents
Drug therapy Download PDFInfo
- Publication number
- CA2239203A1 CA2239203A1 CA002239203A CA2239203A CA2239203A1 CA 2239203 A1 CA2239203 A1 CA 2239203A1 CA 002239203 A CA002239203 A CA 002239203A CA 2239203 A CA2239203 A CA 2239203A CA 2239203 A1 CA2239203 A1 CA 2239203A1
- Authority
- CA
- Canada
- Prior art keywords
- substance
- molecule
- ring
- compound
- conversion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9524942.1A GB9524942D0 (en) | 1995-12-06 | 1995-12-06 | Drug therapy |
GB9524942.1 | 1995-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2239203A1 true CA2239203A1 (en) | 1997-06-12 |
Family
ID=10784998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002239203A Pending CA2239203A1 (en) | 1995-12-06 | 1996-12-06 | Drug therapy |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0865298A1 (it) |
JP (1) | JP2000502071A (it) |
CA (1) | CA2239203A1 (it) |
GB (1) | GB9524942D0 (it) |
WO (1) | WO1997020580A1 (it) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9712370D0 (en) | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
CA2344440A1 (en) * | 1998-09-18 | 2000-03-30 | Immunomedics, Inc. | Antibody directed enzyme prodrug therapy (edept) with glucoronidase |
IL126732A0 (en) * | 1998-10-23 | 1999-08-17 | Intelligene Ltd | Pro drug |
GB0916749D0 (en) * | 2009-09-23 | 2009-11-04 | Mologic Ltd | Peptide cleaning agents |
GB201308363D0 (en) | 2013-05-09 | 2013-06-19 | Bagshawe Kenneth D | Tumour therapy |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
GB9200417D0 (en) * | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Cytotoxic drug therapy |
-
1995
- 1995-12-06 GB GBGB9524942.1A patent/GB9524942D0/en active Pending
-
1996
- 1996-12-06 JP JP9521082A patent/JP2000502071A/ja active Pending
- 1996-12-06 EP EP96940685A patent/EP0865298A1/en not_active Withdrawn
- 1996-12-06 WO PCT/GB1996/003000 patent/WO1997020580A1/en not_active Application Discontinuation
- 1996-12-06 CA CA002239203A patent/CA2239203A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
GB9524942D0 (en) | 1996-02-07 |
WO1997020580A1 (en) | 1997-06-12 |
EP0865298A1 (en) | 1998-09-23 |
JP2000502071A (ja) | 2000-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11278627B2 (en) | Antibody-drug conjugates and the use of same in therapy | |
JP3592711B2 (ja) | 細胞毒性剤治療 | |
Melton et al. | Antibody-enzyme conjugates for cancer therapy | |
US5728868A (en) | Prodrugs of protein tyrosine kinase inhibitors | |
EP0408546B1 (en) | Improvements relating to drug delivery systems | |
EP2709667B1 (en) | Bio-orthogonal drug activation | |
US6511663B1 (en) | Tri- and tetra-valent monospecific antigen-binding proteins | |
JP3373849B2 (ja) | 3価および4価の単一特異性抗原結合性タンパク質 | |
JP3983799B2 (ja) | 細胞および血清タンパク質アンカー並びに接合体 | |
AU2002337954B2 (en) | Integrin targeting compounds | |
WO2014081301A1 (en) | Bio-orthogonal drug activation | |
US5716990A (en) | Drug delivery systems | |
CA2239203A1 (en) | Drug therapy | |
CA2124217A1 (en) | Inactivation of cytotoxic drugs | |
EP0918545B1 (en) | Tumour therapy | |
Hay et al. | Antibody-directed enzyme-prodrug therapy (ADEPT) | |
Knox et al. | Antibody-directed enzyme prodrug therapy: potential in cancer | |
CA2177644A1 (en) | Polymeric prodrugs for beta-lactamase and uses thereof | |
CA2344440A1 (en) | Antibody directed enzyme prodrug therapy (edept) with glucoronidase | |
US20020127229A1 (en) | Tumour therapy | |
MXPA96001871A (en) | Polymeric profarmacos for the beta-lactamasa yusos de los mis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead | ||
FZDC | Correction of dead application (reinstatement) |